- 03 июня 2014, 17:30
- SeekingAlpha.com. Market Currents
- Gilead Sciences' (GILD) oral spleen tyrosine kinase (Syk) inhibitor GS-9973 demonstrates an overall response (OR) rate of 49% and an estimated progression-free survival (PFS) rate of 70% at 24 weeks in patients with relapsed chronic lymphocytic leukemia (CLL) in a 41-patient Phase 2 clinical trial. 95% of the patients experienced tumor shrinkage and 62% experienced tumor reduction of at least 50%.
- Based on these data, the company plans to start new CLL study cohorts to include patients who have relapsed following treatment with other b-cell receptor inhibitors.
НОВОСТИ ПО ТЕМЕ